Medical Oncologist
CION Cancer Clinics
Third-line treatment and beyond for liver cancer | CION Cancer Clinics
A third treatment for liver cancer is sometimes possible, if the liver still works well and you are up and about. The choice is usually a medicine you have not yet had, a clinical trial, or supportive care on its own. Evidence at this stage is thin. This page explains how the decision is made, who a third line suits, and when it is kinder to stop. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Is there any treatment left after two lines have stopped working?
- What decides whether a third treatment makes sense?
- What can actually be offered as a third line?
- What happens when scans show growth on second-line treatment?
- When is a third line more likely to harm than help?
- What this page cannot tell you
- Common questions about third-line liver cancer treatment
The short answer
Is there any treatment left after two lines have stopped working?
Sometimes, yes. For a person whose liver is still working well and who is up and about most of the day, a third medicine can be tried. The evidence for any third line in hepatocellular carcinoma (HCC, the cancer that starts in the liver cells) is much thinner than for the first two, and the honest choice for some families is to put comfort first.
Who this page is for
This page is about primary liver cancer that has kept growing through first-line treatment, usually atezolizumab plus bevacizumab or a tablet, and then through a second-line medicine. If the cancer in the liver spread there from the bowel, breast or another organ, the options are different and are planned around that original cancer.
Why the word "line" matters
A line is one treatment plan used until the scans show growth or the side effects become too much. Each new line tends to work for a shorter time than the one before, because the cancer has already learnt to resist the drugs it has seen. That is not a failure of the patient or the family. It is how this cancer behaves.
No one can tell you from a web page how long a third line will help. Your oncologist will talk about your situation, not an average.What the team weighs
What decides whether a third treatment makes sense?
The name of the next drug matters less than these four things. The tumour board looks at them together.
How well the liver is working
By the third line, the liver has often weakened. Doctors check the Child-Pugh score, a grade built from bilirubin, albumin, clotting and any fluid or confusion. A liver graded C rarely copes with more cancer medicine.
How you are in yourself
Someone who walks, eats and looks after themselves is far more likely to gain from a new drug than someone who spends most of the day in bed.
What has already been used
- Which drug families you have had
- How long each one held the cancer
- Which side effects forced a stop
What you want from the time
Some people want every reasonable chance. Others want fewer hospital visits and more days at home. Both are valid, and the plan should follow the answer.
Not sure whether this applies to you?
Ask an oncologistThe options in practice
What can actually be offered as a third line?
- A tablet not yet used
- If you have had one targeted tablet, another one such as cabozantinib, regorafenib or lenvatinib may still be possible. Cabozantinib was tested in people who had already had more than one treatment.
- Immunotherapy, if never given
- Someone who started on tablets may not yet have had an immune drug such as nivolumab or pembrolizumab. Used alone, these help a smaller group.
- Ramucirumab
- Only for people whose AFP blood marker is high. Availability in India varies, so ask your oncologist before planning around it.
- A clinical trial
- Trials are an option to ask about, not a last resort. Few run in Telangana at any one time, and eligibility is strict.
- Treatment for one growing spot
- Where one area is causing pain or pressing on something, radiation or another local treatment may ease that symptom.
- Supportive care on its own
- Treating pain, fluid, itching and appetite without cancer medicine. It is active care, not giving up.
How the decision is made
What happens when scans show growth on second-line treatment?
The scans are compared properly
The radiologist compares the new CT or MRI with older ones. A tumour can look bigger for a short while on immunotherapy without truly growing, so one scan is not always the final word.
Blood tests check the liver
Bilirubin, albumin, clotting and AFP are repeated. These set the safe limits for anything that comes next.
The tumour board reviews the whole story
Medical oncologists, radiologists and the wider team look at what has been used and how the liver is coping. CION arranges any extra scans through its diagnostic partners.
You hear the options, including stopping
Your oncologist explains what each choice may offer and what it costs in side effects, visits and money. Supportive care is always on that list.
The plan is reviewed often
If a third drug is started, the first scan after it is a real decision point. Carrying on only makes sense if the cancer is held and you feel well enough.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Who this does not suit
When is a third line more likely to harm than help?
A third cancer medicine rarely suits someone whose liver has moved into Child-Pugh C, with deep jaundice, fluid that keeps coming back or repeated confusion. In that liver, the drugs add side effects without giving the cancer much of a fight.
Other situations where caution comes first
People who now spend most of the day in bed, who have lost a lot of weight, or who had serious bleeding on an earlier drug are also unlikely to gain. Bleeding from varices, the swollen veins in the food pipe, is a particular worry with some of these medicines. Someone who had a severe immune reaction on an earlier immunotherapy is usually not given another immune drug.
Stopping is a decision too
Families sometimes feel that saying no to a third drug is abandoning their parent. It is not. Moving the focus to comfort, sleep, eating and time together is a plan, and it is often the plan that gives the most good days. Palliative care can start alongside treatment, long before any decision to stop.
Being straight with you
What this page cannot tell you
It cannot tell you which drug comes next for you, or whether a third line will help at all. That depends on your scans, your blood results and the treatments you have already had, and only a medical oncologist who has seen all of them can weigh it.
It cannot predict time
Families often ask how long a third drug will add. Trial averages do not describe any one person, and this page will not give you a number. Ask your oncologist what they expect for you, and what would make them change course.
It does not cover the drugs themselves
How each medicine works and its side effects are explained in detail on the immunotherapy for liver cancer page and in our pages on the later-line tablets.
If your parent's treatment has stopped working and you want another team to look at it, CION offers second opinions. One helpline serves every centre.Questions we are asked
Common questions about third-line liver cancer treatment
Is there a standard third-line treatment for HCC?
Not one agreed standard. Guidelines are clear on first and second line, but after that the choice depends on which drugs have already been used, how the liver is working and how fit you are. Your oncologist picks from the medicines you have not yet had, a trial, or supportive care.
Can the same drug be tried again later?
Usually not, if it was stopped because the cancer grew on it. If it was stopped only because of side effects, a carefully adjusted restart is sometimes discussed. Your oncologist will explain why a drug was stopped before deciding whether it can come back.
Is ordinary chemotherapy an option at this stage?
It is rarely a good one for HCC. Standard chemotherapy drips work poorly against this cancer and are harder on a damaged liver. Our page on why ordinary chemotherapy barely works explains the reasons, and the few situations where it is still used.
Are these medicines available in India?
Several targeted tablets and immunotherapy drugs are available in India, some as lower-priced generic versions. Availability of individual drugs changes, and some reach India later than elsewhere. Ask your oncologist what can actually be obtained now, and whether a patient assistance programme exists.
How do we know if the third drug is working?
Through repeat scans, blood tests including AFP, and how you feel. A drug that holds the cancer still, without shrinking it, can still be doing useful work. Ask when the first check scan will be and what result would lead to a change.
What if my parent's liver is getting weaker?
A weakening liver often matters more than the cancer itself at this stage. More cancer medicine can bring liver failure sooner. The team may suggest focusing on fluid, jaundice, itching and confusion instead, while still checking regularly how things are going.
Should we look for a clinical trial?
It is reasonable to ask. A trial may offer a newer approach, but it may not turn out better, and eligibility rules often exclude a weaker liver. Ask your oncologist whether any trial fits, and read about whether to join a trial first.
Can CION look at my parent's case now?
Yes. Bring the scan reports and discs, blood results and a list of every treatment given with dates. The tumour board will review it and tell you honestly whether another line is worth trying. Call the CION helpline to arrange this at the nearest centre.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- American Cancer Society — Targeted Drug Therapy for Liver Cancer
- American Cancer Society — Immunotherapy for Liver Cancer
- Cancer Research UK — Treatment for liver cancer
- Macmillan Cancer Support — Liver cancer (hepatocellular carcinoma HCC)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Second-line treatment after first-line failsThe step before this one, and how it was chosenRegorafenib, cabozantinib and ramucirumabThe drugs most often used after first lineDeciding to stop active treatmentHow families make this choice togetherSystemic treatment with Child-Pugh B liver functionWhen a weaker liver limits the options
Talk to us
Has your parent's second treatment stopped working?
Send us the latest scans and blood results and our tumour board will look at what options remain, including whether it is time to focus on comfort. One helpline serves every CION centre.